



(11) **EP 2 068 935 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
14.09.2011 Bulletin 2011/37

(45) Date of publication and mention
of the grant of the patent:
13.04.2011 Bulletin 2011/15

(21) Application number: **07818168.2**

(22) Date of filing: **14.09.2007**

(51) Int Cl.:
A61K 47/48 ^(2006.01) **C07K 14/47** ^(2006.01)
C07K 14/52 ^(2006.01) **A61M 25/00** ^(2006.01)

(86) International application number:
PCT/EP2007/008029

(87) International publication number:
WO 2008/031612 (20.03.2008 Gazette 2008/12)

(54) **POLYMER CONJUGATES OF BOX-A OF HMGB1 AND BOX-A VARIANTS OF HMGB1**
POLYMERKONJUGATE VON BOX-A VON HMGB1 UND BOX-A-VARIANTEN VON HMGB1
CONJUGUES POLYMERES D'UNE BOITE A DE HMGB1 ET VARIANTES DE LA BOITE A DE HMGB1

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE
SI SK TR
Designated Extension States:
AL BA HR MK RS

(30) Priority: **15.09.2006 EP 06019362**
05.03.2007 US 904776 P

(43) Date of publication of application:
17.06.2009 Bulletin 2009/25

(73) Proprietor: **Creabilis Therapeutics s.r.l.**
10010 Colletterto Giacosa (TO) (IT)

(72) Inventors:
• **TRAVERSA, Silvio**
10010 Palazzo Canavese (IT)
• **LORENZETTO, Chiara**
10068 Villafranca Piemonte (IT)
• **MAINERO, Valentina**
10015 Ivrea (TO) (IT)
• **MORENA, Sebastiano**
10034 Chivasso (IT)

• **FUMERO, Silvano**
10015 Ivrea (IT)
• **BECCARIA, Luca**
10015 Ivrea (IT)

(74) Representative: **Weiss, Wolfgang et al**
Weickmann & Weickmann
Patentanwälte
Postfach 86 08 20
81635 München (DE)

(56) References cited:
WO-A-02/092004 WO-A-2006/012373
WO-A-2006/024547

• **YAMADA ET AL: "New high mobility group box 1 assay system" CLINICA CHIMICA ACTA, AMSTERDAM, NL, vol. 372, no. 1-2, 23 June 2006 (2006-06-23), pages 173-178, XP005623667 ISSN: 0009-8981**
• **PASUT G. ET AL: 'Protein, peptide and non-peptide drug PEGylation for therapeutic application' EXPERT OPINION ON THERAPEUTIC PATENTS vol. 14, no. 6, 2004, pages 859 - 893, XP001202106**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 068 935 B8